MCA-0994: Open label single arm study of the safety pharmacokinetics and antiretroviral activity of the combination of 3BNC117-LS and 10-1074-LS in viremic HIV-infected individuals
Brief description of study
The purpose of this research study is to evaluate if one dose of two antibodies is safe, if it causes side effects, and to measure the time it takes for the antibodies to clear from the blood. The study will also test if the two antibodies can lower the amount of HIV (viral load) in the blood.
HIV is the virus that causes AIDS. The antibodies we are testing in this study, 3BNC117-LS and 10-1074-LS, are antibodies made in the laboratory.
An antibody is a substance that the body makes in response to an infection. These antibodies attach to HIV and can block HIV from attaching to cells and spreading to other parts of the body. These antibodies are being developed to potentially treat and prevent HIV infection.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
HIV,AIDS,antiretroviral
-
Age: Between 18 Years - 99 Years
-
Gender: All
To join this research, you must have:
• Confirmed HIV-1 infection and be off ART with HIV viral load between 500 and 100,000 copies/ml.
• Current CD4+ T cell count higher than 300 cells/µl.
• If you are a sexually active male or female and participating in sexual activity that could lead to pregnancy, you must agree to use two effective methods of contraception from 10 days prior to and six months after receiving the research drug.
Updated on
15 Dec 2021.
Study ID: 844068
